Immunotherapies, biological and targeted therapies
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

Search Term: Immunology, Biological therapies and targeted therapies
Please scroll down past the trials to see pages on this site about this topic!

  Treatment Location Last Updated
Details A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Durham, NC USA 07/31/2008
Details A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Omaha, NE USA 07/31/2008
Details A Phase II/III Randomized Study of CDX-110 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme San Francisco, CA USA 07/23/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Chicago, IL USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Detroit, MI USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Durham, NC USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Charlottesville, VA USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Cleveland, OH USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Cleveland, OH USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Hackensack, NJ USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Syracuse, NY USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Chicago, IL USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Los Angeles, CA USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Boston, MA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme New Haven, CT USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Buffalo, NY USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Salt Lake City, UT USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Columbus, OH USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Evanston, IL USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Palo Alto, CA USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme New York, NY USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Philadelphia, PA USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Houston, TX USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Seattle, WA USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme New York, NY USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Jacksonville, FL USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme San Francisco, CA USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Saginaw, MI USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Gainsville, FL USA 07/03/2008
Details A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme San Antonio, TX USA 07/03/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma Chicago, IL USA 06/28/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma Detroit, MI USA 06/28/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma Charlotte, NC USA 06/28/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma Atlanta, GA USA 06/28/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma Orlando, FL USA 06/28/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma Birmingham, AL USA 06/28/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma Saint Louis, MO USA 06/28/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma Salt Lake City, UT USA 06/28/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma St. Louis, MO USA 06/28/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma Birmingham, AL USA 06/28/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma Duarte, CA USA 06/28/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma Orlando, FL USA 06/28/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma Tampa, FL USA 06/28/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma Cambridge, MA USA 06/28/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma Cambridge, MA USA 06/28/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma Seattle, WA USA 06/28/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma Duarte, CA USA 06/28/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma Los Angeles, CA USA 06/28/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma Chicago, IL USA 06/28/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma Baltimore, MD USA 06/28/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma Grand Rapids, MI USA 06/28/2008
Details A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma Dallas, TX USA 06/28/2008
Details Study of a Drug [DCVax®-Brain] to Treat Newly Diagnosed GBM Brain Cancer Cincinnati, Oh USA 06/04/2008
Details A Phase II Trial of Thalidomide in combination with Temozolomide or CPT-11 in patients with recurrent anaplastic gliomas or glioblastoma multiforme Houston, TX USA 04/16/2008
Details A Phase II Study of Rituximab and Temozolomide in Recurrent Primary CNS Lymphoma Houston, TX USA 04/16/2008
Details Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients with Recurrent Malignant Glioma Houston, TX USA 04/15/2008
Details A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma Houston, TX USA 04/15/2008
Details Phase 2, 2-part, multicenter, open-label study to evaluate the safety, tolerability, and efficacy of CT-322 (Angiocept™) monotherapy and combination therapy with irinotecan in patients with recurrent glioblastoma multiforme Houston, TX USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Durham, NC USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Houston, TX USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Los Angeles, CA USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma New York, NY USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma San Antonio, TX USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Bethesda, MD USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Houston, TX USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Madison, WI USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Pittsburgh, PA USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Boston, MA USA 04/15/2008
Details Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas Durham, NC USA 04/15/2008
Details Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas Houston, TX USA 04/15/2008
Details Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas Los Angeles, CA USA 04/15/2008
Details Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas San Francisco, CA USA 04/15/2008
Details Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas Madison, WI USA 04/15/2008
Details Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas New York, NY USA 04/15/2008
Details Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas San Antonio, TX USA 04/15/2008
Details Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas Bethesda, MD USA 04/15/2008
Details Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas Pittsburgh, PA USA 04/15/2008
Details Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas Boston, MA USA 04/15/2008
Details A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas New York, NY USA 04/15/2008
Details A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas Durham, NC USA 04/15/2008
Details A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas Houston, TX USA 04/15/2008
Details A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas Los Angeles, CA USA 04/15/2008
Details A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas Bethesda, MD USA 04/15/2008
Details A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas Boston, MA 04/15/2008
Details Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Houston, TX USA 04/11/2008
Details Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Phoenix, AZ USA 04/11/2008
Details Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Springfield, MO USA 04/11/2008
Details Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Greenville, SC USA 04/11/2008
Details Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Spartanburg, SC USA 04/11/2008
Details Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Galveston, TX USA 04/11/2008
Details Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Kalamazoo, MI USA 04/11/2008
Details Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme San Antonio, TX USA 04/11/2008
Details Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Akron, OH USA 04/11/2008
Details Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Kingsport, TN USA 04/11/2008
Details Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Newark, DE USA 04/11/2008
Details Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Jacksonville, FL USA 04/11/2008
Details Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Mobile, AL USA 04/11/2008
Details Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Sacramento, CA USA 04/11/2008
Details Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Columbus, GA USA 04/11/2008
Details Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Harvey, IL USA 04/11/2008
Details Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Saint Louis Park, MN USA 04/11/2008
Details Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Marlton, NJ USA 04/11/2008
Details Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Akron, OH USA 04/11/2008
Details Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Canton, OH USA 04/11/2008